Adcendo’s Post

📣 The survival of patients with metastatic melanoma is improving in Denmark! 🛑 Still, a big unmet need exists 👉https://lnkd.in/dzmPq37Q (European Journal of Cancer, Oct 20th 2023) A new manuscript from CCIT - Center for Cancer Immune Therapy, Denmark by Aimilia Schina, Sidsel Pedersen et al. (PI: Marco Donia, TIL group https://lnkd.in/dsj-4W6u), shows that the real-world survival of patients with metastatic melanoma in Denmark has improved significantly since the introduction of anti-PD-1 in clinical practice. 1️⃣Sustained, improved real-world survival >5 years after introducing anti-PD-1 in melanoma 2️⃣Survival improved regardless of clinical trial eligibility 3️⃣Six baseline clinical characteristics can predict real-world survival 4️⃣Data-driven, tailored prognostic assessment can be used for patient information There has been steady improvement in survival over the previous decade, but a big unmet need still exists. Even patients diagnosed in 2018 (when 1st line anti-PD-1, Anti-PD1 plus anti-CTLA-4, and BRAFi+MEKi were available) had a median survival below two years. #melanoma #melsm #RWE #RWD #immunotherapy #dksund Kræftens Bekæmpelse Anne Louise Spenning, Olivia Kaas Laursen, Cecilia Pedersen, Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt (onkologisk afd), Inge Marie Svane, Eva Ellebæk

Did you know that 1 in 4 cancers diagnosed in Australia are rare or less common? Wednesday 26th June is Rare Cancers Awareness Day, a day to highlight rare cancers and the unique challenges patients and clinicians face in treating them. Most blood cancers are rare cancers, including Acute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukaemia (ALL), Myelodysplasia Syndrome (MDS), and Multiple Myeloma. The only way to advance new, effective treatments for patients with rare blood cancers is through clinical trial research. ALLG has had 5 decades of impact through our blood cancer research, improving treatments for patients through international and local collaborations and world-class clinical trials. We are dedicated to researching innovative new ways to treat rare blood cancers, such as CAR-T cell therapies, immunotherapies and precision medicine, that deliver Better treatments, better quality of life, and potentially a cure. Discover more about our clinical blood cancer trials and the impact of our organisation at allg.org.au #WeAreRare #ALLG #ALLGtrials #bettertreatmentsbetterlives #clinicaltrials #bloodcancer #bloodcancerawareness #bloodcancercure #bloodcancers #haematology #haematologyresearch #leukaemiaandlymphoma #myeloma #myelomaawareness

The lack of organised data collection on #pancreaticcancer hinders our understanding and the development of effective diagnosis and treatments. Comprehensive data is important for oncological research. Our Goals: 👉 Establish a European network of registries and biobanks to collect standardised data on patients, treatments, and outcomes. 👉 Create shared guidelines for data and sample collection to unify research efforts. Learn more in our position paper and help us raise awareness: https://shorturl.at/fgyE8 #EUelections2024 Cancer Patients Europe - CPE Digestive Cancers Europe European Pancreatic Club UEG - United European Gastroenterology

April is Bowel Cancer Awareness Month. Bowel cancer is a general term for cancer that begins in the large bowel. Depending on where the cancer starts, bowel cancer is sometimes called colon or rectal cancer. The lifetime risk of developing colorectal cancer (CRC) is about 1 in 23 for men and 1 in 25 for women, and it accounts for the highest number of cancer-associated deaths globally. While the survival rate of CRC patients with early-stage disease is as high as 80%, overall survival for patients where cancer has spread to sites such as the liver (metastatic colorectal cancer mCRC) is drastically reduced to 20%. These low survival rates necessitate the identification of novel diagnostic and therapeutic strategies that can allow better diagnosis and treatment of mCRC patients. Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a novel biomarker panel to identify patients with colorectal cancer who are at high risk of developing metastatic disease. Dr Sudipto Das and his research team are seeking industry partners to co-develop this predictive test and/or functionally validate the new therapeutic targets in mCRC. To find out more, please contact Dr Derek John #bowelcancer #mCRC #cancerawareness

#rarediseaseday2024 #bitesizelearning 𝗗𝗲𝗹𝗮𝘆𝗲𝗱 𝗼𝗲𝘀𝗼𝗽𝗵𝗮𝗴𝗲𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗶𝘀 𝗮 𝗽𝗿𝗼𝗯𝗹𝗲𝗺 Oesophageal squamous cell carcinoma (OSCC) is an aggressive form of oesophageal cancer that is often diagnosed only once the cancer has already spread. This means survival rates for OSCC are much lower than some other cancers. For the best chance on a positive outcome, early diagnosis is critical: • The 5-year relative survival rate for people with localised 𝗼𝗲𝘀𝗼𝗽𝗵𝗮𝗴𝗲𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 is 49%. • If the tumour has spread to nearby tissue or the regional lymph nodes, the 5-year relative survival rate is only 28%. • If the tumour has spread to distant areas of the body, the relative 5-year survival rate drops to a little as 6%. Gaining a better understanding of the early stages of OSCC is crucial so that patients can be diagnosed and treated earlier than is currently possible. At Volv Global SA, we apply cutting edge machine-learning techniques to help doctors process the many pieces of health information they are dealing with on a daily basis, to help them triage those people most at risk of unknowingly living with a difficult to diagnose disease for earlier diagnosis. To learn more about our work, and how we aim to help improve the outlook for oesophageal cancer patients, please get in touch! See comments below for contact details and source references. #earlydetection #rarediseaseawareness #rarecancer #oesophagealcancer #inTrigue With Volv Global SA, , Rare Disease Day and others.

👏🎉Congratulations to California Life Sciences (CLS) member company Guardant Health for being recognized by TIME Magazine on their "Time 100 Most Influential Companies 2024" list, for their innovative blood-based colorectal cancer (CRC), cancer screening test under current review by US FDA. As read in TIME Magazine, "A new era of cancer detection is under way, using simple blood tests. In 2022, Guardant Health introduced Shield, one of the first blood-based tests to screen for colorectal cancer. While it wouldn’t replace colonoscopies, the gold standard for detection, the relative ease of the breakthrough test can significantly increase the number of people who are diagnosed earlier with colorectal cancer." You can catch members of the Guardant team at #BIO24 to learn more or read the full article here: https://bit.ly/3Xa2nnZ #CancerMoonShot #Shield #GuardantHealth

March marks Colorectal Cancer (CRC) Awareness Month. CRC is the third most common cancer worldwide with more than 1.9 million new cases. The incidence and impact of CRC can be significantly reduced by early detection through screening. At Guardant Health, we are transforming cancer care for patients with CRC across all stages of the disease. We offer next generation sequencing tests which screen for CRC, monitor for recurrence and guide treatment decisions for advanced stage cancer. Check out this publication (https://lnkd.in/gcbU3XRe) where our Guardant360® assay demonstrated that serial ctDNA monitoring appears to be a feasible approach to identify acquired alterations with therapeutic implications in this large cohort of patients with mCRC. Visit us at https://lnkd.in/gHNdYtQN to find out more about our comprehensive genomic profiling tests which can help guide treatment decisions for patients with cancer. Information referenced from https://lnkd.in/grV2Usgp and accessed on 19 February 2024. #guardanthealth #guardanthealthamea #colorectalcancerawarenessmonth #colorectalcancerscreening #cancerpatients #CRC #comprehensivegenomicprofiling #precisiononcology #liquidbiopsy #liquidissolid #cancercarecontinuum

July is Sarcoma and Bone Cancer Awareness Month. While rare in older adults, certain inherited conditions or environmental factors can increase the risk of developing these types of cancer.¹ See how adding Galleri to your recommend cancer screenings can give you the chance to screen for many of the deadliest cancers, including those without recommended screenings today: Galleri.com
 #SarcomaAwarenessMonth #BoneCancerAwarenessMonth #CancerAwareness
 See Important Safety Information: http://bit.ly/33m8pFa
 Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
 Galleri’s overall sensitivity in study participants with sarcoma was 60.0% (40.0% for stage I, 100.0% for stage II, 50.0% stage III, 85.7% stage IV). Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a “Cancer Signal Detected” result. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.

February 4 is #WorldCancerDay, an important time to reflect upon the significant progress that has been made in the fight against cancer, and the unprecedented innovations that are making a meaningful impact on patients around the world.   Recent advancements in science and technology have led to the introduction of CAR T cell therapies, a transformational treatment option which involves harnessing the power of a patient’s own immune system to target their cancer.   Since their introduction in 2019, Kite’s CAR T-cell therapies have been addressing unmet needs in hematologic cancers, helping Canadians with certain types of blood cancer achieve unprecedented rates of survival. Today, more than 17,000 patients have been treated globally, and over 500 Canadians’ have received one of Kite’s CAR T therapies.   CAR T cell therapy has already become recognized as the standard of care for certain types of blood cancers. As we look toward the future, there is a significant focus on expanding CAR T therapies to a wider range of diseases and earlier lines of treatment, offering more hope to more Canadians impacted by advanced or difficult-to-treat cancers.   To fully realize the potential of CAR T therapies on the horizon, we must work together now to ensure Canada’s healthcare system has the capacity to deliver these innovations to Canadian patients across the country – no matter where they live. Kite is committed to working collaboratively with stakeholders and decision-makers to help ensure that as many people as possible may benefit from these potentially life-saving therapies.   #CloseTheCareGap #GileadProud

Prostate Cancer UK’s TRANSFORM trial is certainly an exciting development in the quest for an effective prostate cancer screening program. We remain hopeful for a clear consensus for the future. However, if you are at higher risk of prostate cancer, you shouldn't wait. Men at higher risk of prostate cancer include: ✔️men with a family history of the disease, ✔️men of African descent, and ✔️men over the age of 50. If you fall into any of these high-risk categories, or are generally worried about any prostate symptoms, we encourage you to speak with us today to discuss your options for assessment, screening, and management. At CAS Medical, we understand the importance of early detection and prompt action when it comes to prostate cancer. Our experienced team can guide you through the available screening methods, such as PSA tests and digital rectal examinations and help you make informed decisions about your health. The TRANSFORM trial results could prove a new milestone in the battle against prostate cancer. If you're at high risk or concerned about symptoms, take proactive steps today by contacting us to explore your screening and treatment options. Early detection and timely intervention can make a significant difference in the fight against prostate cancer. Contact us today 🌐 https://lnkd.in/eYJavCPU 📞 0141 280 6956 #ProstateCancer #MensHealth #CASMedical #PreventionIsKey